IMI AMR ACCELERATOR

This webinar is a joint effort by @era4tb.bsky.social, GNANOW and COMBINE under AMR Accelerator

In our latest study under RespiriNTM, zebra fish helped our researchers model nontuberculous mycobacterial infection.

Why?
Their immune system mirrors humans, letting us study infections effectively and ethically.

👉 Read more at: https://bit.ly/4pS8HwB
👉 Open manuscript: https://bit.ly/3KzNEi8

We are bringing you our latest webinar on Hollow Fibre Assays in antimicrobial drug development, featuring three leading experts.

👉 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁:
Building effective hollow fibre systems
Case studies
Applications in 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 PK/PD models

👉 Register now: https://bit.ly/3VN3Sa5

Medicines need a reliable teammate to work effectively against resistant bacteria.
And Alpibectir is that teammate boosting ethionamide (Eto) to fight resistant bacteria.

👉 Read the complete paper to see the impact of Alpibectir in a first-in-human TRIC-TB study: https://bit.ly/48c5odi

Video Conferencing, Web Conferencing, Webinars, Screen Sharing Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom ...

ERA4TB Webinar 📣

How can health systems respond to #AMR through innovation & evidence-based policy? 🌍✨

🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from NICE & WHO

👉 Register: tinyurl.com/ERA4TB

@amr-accelerator.bsky.social @amr-accelerator.bsky.social @tballiance.bsky.social

Our researchers found a missing link in applying ML to AMR: lack of clinical and preclinical data.

We highlighted the key milestones from data collection to ML models in building the first and public FAIR MIC dataset & AntiMicrobial-KG.

Listen to webinar to learn more: bit.ly/472Q8y4

In our latest study, under UNITE4TB consortium, researchers describe how AI could become a powerful ally against TB at the same time highlight challenges that come with this new tech.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/3Is4E9m

ERA4TB Webinar 📣

How can health systems respond to #AMR through innovation & evidence-based policy? 🌍

Join our ERA4TB webinar

🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from @NICEComms & @WHO

👉 Register: tinyurl.com/ERA4TB

@amr-accelerator.bsky.social @who.int @nicecomms.bsky.social

Collaboration in AMR R&D is multisectoral, but not every question moves a project forward. Early scientific advice from EMA is key to understanding what to ask (and not to).
🎥 Watch the complete webinar at: https://bit.ly/4mpXPTx

ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for #tuberculosis.

Across the EU/EEA, resistant infections add over 9.5M extra hospital days annually. In a study conducted under PrIMAVeRa, our researchers used Bayesian analysis to show each resistant infection adds ~1–2 days, with variable extra costs.

👉 Read more: https://bit.ly/468S1co

Of all the buzzwords this year, none spread faster than "superbugs"! Used in the titles or main public messaging by over half a dozen of major news stories & campaigns (Mar–Sep 2025). Catchy, but does it oversimplify AMR or mislead the public?

Share your thoughts on main drawback of this framing.

@era4tb.bsky.social researchers found compounds that block TB’s ESX-1 system (used to damage immune cells) while also improving effectiveness of ethionamide. A dual-action step against drug-resistant TB.

👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: bit.ly/3VJJJBw

Why understanding the right dose matters in anti-TB treatment?
We broke it down 👇 for you from the start to finish.

👉 Join the UNITE4TB & ERS webinar to learn more on methods that are being used to understand optimal dosing in depth
🔗 https://bit.ly/45QUyYB

“Supercontactors” are the hubs of hospital networks. Controlling their interactions, can help dramatically slow down the spread. Our latest PrIMAVeRa study showcases that targeting them reduced MRSA cases by about 20%.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/468hBgo

In AMR research, success rarely comes easy. From LpxH inhibitors under Uppsala University to PhagoMed’s pivot (now BioNTech) and Disperazol’s 15-year journey, each story shows how barriers can be turned into pathways for progress.
👉 Hear their lessons and takeaways here: https://bit.ly/47n6d2v

TB bacteria inhabits the air we breathe, exposing most people unknowingly. Yet only 5–10% develop active disease. Research under RespiriNTM and RespiriTB tested amiodarone, to boost immunity by enhancing autophagy against TB.

👉 Read: https://bit.ly/47QD53J

Regulators are not just “approvers,” in AMR R&D they guide the path.
The WHO 2025 AMR plan stresses how early advice, adaptive pathways & collaboration can speed safe, effective solutions.

Lets us know in comments 👇, do you know what support regulators give developers?

Is monitoring aggregate AMR data enough, or does it hide the gaps? Resistance varies across Europe, and overall prevalence masks the highest-burden regions. The PrIMAVeRa study maps pathogen-specific morbidity and mortality.
👉 Read more: https://bit.ly/3UCvWwk

In 2020, 1,800 immuno-oncology drugs were in development, and only 41 new antimicrobials made trials. Meanwhile, 10.8M people fell ill with TB in 2023.

Why such a huge gap?
We broke it down into clinical & commercial barriers in TB drug development.

Learn more at: https://youtu.be/n6NxPFxHOys

𝗜𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗧𝗕 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲?
Yes it can be, if patients can continue.
𝗧𝗵𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲?
Complex dosing regimens reduce adherence.

A UNITE4TB study, models 𝗼𝗻𝗰𝗲-𝗱𝗮𝗶𝗹𝘆 regimens for bedaquiline and delamanid.

👉Read here: https://bit.ly/45estKn

TB care starts in communities, where CSOs help guide and support care, adherence & recovery. True progress needs equal partnerships, yet the sustained funding lags.

Join UNITE4TB & ERS panel on meaningful TB community engagement: bit.ly/412Cyrf

𝗛𝗼𝘄 𝘁𝗼 𝘁𝗿𝗮𝗰𝗲 𝗧𝗕 𝗱𝗿𝘂𝗴 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗿𝗮𝗱𝗶𝗼𝘁𝗿𝗮𝗰𝗲𝗿𝘀? With more safer and faster approach?
Researchers under TRIC-TB consortium used ¹⁹F-NMR, ¹H-NMR & HR-MS to profile alpibectir.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁 https://bit.ly/4muyHLJ

Everyone in the antimicrobial resistance ecosystem stands to gain clearer direction, better tools and stronger collaboration with this WHO roadmap (2024–2030).

AMR is not just scientific or clinical problem, but a systemic challenge needing multisectoral solutions.

🔗 https://bit.ly/4opZATc

TB survives by fueling its metabolism through a tricky enzyme, cytochrome bc1:aa3.

So how do we starve it?
Inhibiting isn’t enough, we need to know exactly how it’s blocked.

Our new study under Respiri TB, reveals this in detail.
👉 Swipe to learn more
🔗 Full paper: https://bit.ly/4oeme0A

@era4tb.bsky.social

Last week, we got together to focus on a key part of TB research: advancing animal models. Six ERA4TB experts discussed how ethical animal models can drive better treatments for drug-resistant TB and speed up testing of new therapies. While the webinar was internal, the impact is global.

The honest reality check on AMR transmission models every researcher needs. Clarity on what works, what is missing and how to build trust.

👉 Swipe to learn the insights
👉 Read more: bit.ly/46UMqXO

#AMR #TB #antimicrobialresistance #research

@era4tb.bsky.social @ihieurope.bsky.social

Juan Calvet (@uc3m.es) presented a poster on the integration of molecular biomarkers into time-kill assays for evaluating new anti-TB drug candidates.

@amr-accelerator.bsky.social
@ihieurope.bsky.social
#Tuberculosis #TB #TranslationalResearch #Biomarkers #TimeKillAssays